Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Antimicrob Chemother ; 78(4): 975-982, 2023 04 03.
Artículo en Inglés | MEDLINE | ID: mdl-36760088

RESUMEN

BACKGROUND: Several countries have recently reported the detection of ESBL-producing Shigella sonnei associated with transmission among MSM. In a previous study by our group, 2.8% of Shigella spp. obtained from MSM in Barcelona between 2015 and 2019 were ESBL producers. OBJECTIVES: To describe and characterize the emerging ESBL-producing Shigella spp. associated with sexual transmission among MSM detected from 2020 to 2021 in Barcelona, elucidating their connectivity with contemporaneous ESBL-producing Shigella spp. from other countries. RESULTS: From 2020 to 2021, we identified that among MSM, 68% of S. sonnei were XDR harbouring blaCTX-M-27 and 14% of Shigella flexneri were MDR harbouring blaCTX-M-27. WGS analysis showed that the ESBL-producing S. sonnei were part of a monophyletic cluster, which included isolates responsible for the prolonged outbreak occurring in the UK. Our data also reveal the first emergence and clonal dissemination of ESBL-producing and fluoroquinolone-resistant S. flexneri 2a among MSM. CONCLUSIONS: We report an increasing trend of antimicrobial resistance in Shigella spp. among MSM in Barcelona since 2021, mainly as a consequence of the dissemination of XDR ESBL-producing S. sonnei, previously reported in the UK. These results highlight the importance of international collaborative surveillance of MDR/XDR S. sonnei and S. flexneri for rapid identification of their emergence and the prevention of the transmission of these pathogens.


Asunto(s)
Disentería Bacilar , Minorías Sexuales y de Género , Shigella , Masculino , Humanos , Shigella flexneri , Shigella sonnei , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Disentería Bacilar/epidemiología , Disentería Bacilar/tratamiento farmacológico , Homosexualidad Masculina , Farmacorresistencia Bacteriana , Pruebas de Sensibilidad Microbiana , Brotes de Enfermedades
2.
Emerg Infect Dis ; 28(5): 967-976, 2022 05.
Artículo en Inglés | MEDLINE | ID: mdl-35447067

RESUMEN

Bordetella pertussis not expressing pertactin has increased in countries using acellular pertussis vaccines (ACV). The deficiency is mostly caused by pertactin gene disruption by IS481. To assess the effect of the transition from whole-cell vaccine to ACV on the emergence of B. pertussis not expressing pertactin in Spain, we studied 342 isolates collected during 1986-2018. We identified 93 pertactin-deficient isolates. All were detected after introduction of ACV and represented 38% of isolates collected during the ACV period; 58.1% belonged to a genetic cluster of isolates carrying the unusual prn::del(-292, 1340) mutation. Pertactin inactivation by IS481 insertion was identified in 23.7% of pertactin-deficient isolates, arising independently multiple times and in different phylogenetic branches. Our findings support the emergence and dissemination of a cluster of B. pertussis with an infrequent mechanism of pertactin disruption in Spain, probably resulting from introduction of ACV.


Asunto(s)
Bordetella pertussis , Tos Ferina , Proteínas de la Membrana Bacteriana Externa/genética , Humanos , Vacuna contra la Tos Ferina , Filogenia , España/epidemiología , Factores de Virulencia de Bordetella/genética , Tos Ferina/epidemiología , Tos Ferina/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA